195 related articles for article (PubMed ID: 37298656)
1. Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.
Fuentealba-Manosalva O; Mansilla M; Buelvas N; Martin-Martin A; Torres CG; López-Muñoz RA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298656
[TBL] [Abstract][Full Text] [Related]
2. Combenefit: an interactive platform for the analysis and visualization of drug combinations.
Di Veroli GY; Fornari C; Wang D; Mollard S; Bramhall JL; Richards FM; Jodrell DI
Bioinformatics; 2016 Sep; 32(18):2866-8. PubMed ID: 27153664
[TBL] [Abstract][Full Text] [Related]
3. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Budman DR; Calabro A; Kreis W
Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
[TBL] [Abstract][Full Text] [Related]
4. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets.
Zheng S; Wang W; Aldahdooh J; Malyutina A; Shadbahr T; Tanoli Z; Pessia A; Tang J
Genomics Proteomics Bioinformatics; 2022 Jun; 20(3):587-596. PubMed ID: 35085776
[TBL] [Abstract][Full Text] [Related]
5. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
[TBL] [Abstract][Full Text] [Related]
7. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
[TBL] [Abstract][Full Text] [Related]
8. SNSynergy: Similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations.
Huangfu X; Zhang C; Li H; Li S; Li Y
Comput Biol Chem; 2024 Jun; 110():108054. PubMed ID: 38522389
[TBL] [Abstract][Full Text] [Related]
9. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
[TBL] [Abstract][Full Text] [Related]
10. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
11. SynergyFinder 2.0: visual analytics of multi-drug combination synergies.
Ianevski A; Giri AK; Aittokallio T
Nucleic Acids Res; 2020 Jul; 48(W1):W488-W493. PubMed ID: 32246720
[TBL] [Abstract][Full Text] [Related]
12. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
[TBL] [Abstract][Full Text] [Related]
13. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
14. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
Amzallag A; Ramaswamy S; Benes CH
BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
[TBL] [Abstract][Full Text] [Related]
15. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
Abd El-Hafeez T; Shams MY; Elshaier YAMM; Farghaly HM; Hassanien AE
Sci Rep; 2024 Jan; 14(1):2428. PubMed ID: 38287066
[TBL] [Abstract][Full Text] [Related]
16. Network Propagation Predicts Drug Synergy in Cancers.
Li H; Li T; Quang D; Guan Y
Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
[TBL] [Abstract][Full Text] [Related]
17. SynergyFinder: a web application for analyzing drug combination dose-response matrix data.
Ianevski A; He L; Aittokallio T; Tang J
Bioinformatics; 2017 Aug; 33(15):2413-2415. PubMed ID: 28379339
[TBL] [Abstract][Full Text] [Related]
18. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.
Malyutina A; Majumder MM; Wang W; Pessia A; Heckman CA; Tang J
PLoS Comput Biol; 2019 May; 15(5):e1006752. PubMed ID: 31107860
[TBL] [Abstract][Full Text] [Related]
19. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
Sharma A; Rani R
J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
